Moderna Inc. announced a significant reduction in its 2025 sales forecast, citing a slow start for its respiratory syncytial virus (RSV) vaccine and diminished demand for COVID-19 vaccines. The company now anticipates sales to range between $5 billion and $7 billion for the year, down from previous expectations. This adjustment comes as Moderna’s stock tumbled to a record low not seen since the early days of the COVID-19 pandemic. Moderna’s President Stephen Hoge remarked on the slower than anticipated uptake of the RSV vaccine, echoing a broader trend where booster shots for COVID vaccines have not met projections. ‘We have seen a slower ramp-up of the RSV vaccine,’ said Hoge. Following this announcement, the company’s shares plummeted, reflecting investor concerns about future revenue streams. Analysts are increasingly scrutinizing revenue forecasts for COVID-19 vaccines as the world adjusts to living with the virus amid decreasing booster shot rates. Despite the challenging market conditions, Moderna continues to focus on its expanding pipeline, which includes various mRNA-based treatments and vaccines. Some experts remain optimistic about the company’s long-term strategies but recognize the immediate challenges it faces in a post-pandemic landscape.
